Vaxart (VXRT) is a leader in developing an oral vaccine for COVID-19 that would make it significantly easier to vaccinate the world, suggests John McCamant, an industry leading biotechnology expert and editor of The Medical Technology Stock Letter.
A pill can be stored at room temperature, no freezer/refrigeration required, given anywhere, no syringe/nurse required, provides mucosal immunity, stops virus before entering bloodstream.
VXRT is poised to deliver Phase 1/II data shortly for VXA-CoV2-1 which upon success will position it as a leader in the second wave of COVID-19 vaccines.
The company's unique vaccine pill should garner both corporate and government partnerships around the world as the easy to manufacture, off the shelf oral vaccine addresses many of the shortcomings of 1st generation vaccines.
In addition, Vaxart is on Operation Warp Speed’s radar and is currently conducting a non-human primate study.
In our view, positive Phase I/II data will serve as a major catalyst for VXRT in 2021. The stock is a "buy" under $15 with a target price of $30 per share.
MoneyShow’s Top 100 Stocks for 2021
The top performing newsletter advisors and analyst are back, and they just released their best stock ideas for 2021. Get your FREE copy of MoneyShow’s 2021 Top Picks report here and see why the nation's leading investment experts believe these stocks will significantly outperform the market in 2021.
Meanwhile, our Top Pick last year was Sangamo Therapeutics (SGMO), which rose 86%. The stock recently hit a 52-week high, with its hemophilia A gene therapy with partner Pfizer (PFE), sympathy with the very strong CRSPR stocks and the potential for M&A.
In 2021, we expect updates from their gene therapy and gene editing platforms in hemophilia A, sickle cell, CAR-T and Fabry disease to create value. SGMO is a "buy" under $20 with a target price of $30 a share.
